Programme


Thursday 29 January - Day one 
11.45amRegistration, lunch, exhibition and poster viewing 
12.30pmWelcome and introduction
Dr Matthew Williams, Consultant Clinical Oncologist, Imperial College Healthcare NHS Trust, and Julian Cahill, Consultant, The National Centre for Stereotactic Radiosurgery
12.50pm
Session 1: Novel imaging in SRS

  • Could rCBV Values Prior to SRS be Used to Predict Progression Status of Brain Metastases?
    Heather Rowe, Clinical Scientist, Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust
  • Beyond Conventional MRI: Advanced Imaging in Post-SRS Treatment Response Assessment
    Dr Markand Patel, Consultant Neuroradiologist, Imperial College Healthcare NHS Trust
  • Evaluating early changes in the post-radiosurgery vestibular schwannoma microenvironment: a multinuclear MRI study
    Dr Daniel Lewis, ST6 Neurosurgical Trainee, North-West Deanery, NIHR Clinical Lecturer, University of Manchester
  • Optimal imaging for planning AVMs
    Dr George Tse, Consultant Interventional Neuroradiologist, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust
  • Discussion
1.50pmSession 2: Single session versus hypofractionation for benign targets

  • Cyberknife radiosurgery and hypofractionated stereotactic radiotherapy for larger vestibular schwannomas
    Dr Amy Irwin, Clinical Oncology ST6, University Hospitals Birmingham 
  • Radiological and Clinical Outcomes in Benign Meningiomas: A Comparison of Single-Fraction versus Multi-Fraction Radiosurgery
    Dr Natasha Chaudhury, Clinical Oncology Registrar, Royal Marsden Hospital Trust
  • Outcomes using Cyberknife Radiosurgery and Hypofractionated Stereotactic Radiotherapy for Meningiomas
    Dr James Riley, Clinical Oncology Registrar, Queen Elizabeth Hospital Birmingham
  • Hypofractionation for benign tumours
    Dr Paul Sanghera, Consultant Clinical Oncologist, University Hospitals Birmingham
2.40pm
Session 3: Sponsored Presentations (I)

  • Leksell Gamma Knife treatment statistics
    Per Nylund, Chairman Leksell Gamma Knife Society, Elekta
  • The power of AI for auto-contouring of brain metastases
     David James, Sr. Marketing Manager Radiosurgery, Siemens Healthineers International AG
3.00pmRefreshments, exhibition and poster viewing
3.30pmSession 4: Use of PTVs and managing uncertainty in SRS

  • Keynote: The Case for margins in SRS
    Professor Marcel Van Herk, Chair in Radiotherapy Physics, Group Leader Adaptive Radiotherapy, The University of Manchester, The Christie NHS Foundation Trust
  • The case against margins in SRS
    Ian Paddick, Consultant Physicist, Medical Physics Limited
  • Discussion
4.10pmSession 5: Approaches and outcomes from SRS for brain metastases: Case reports

  • Multi-arc non-coplanar VMAT - can extracranial dose be reduced without compromising plan quality
    Esmé Votta, Radiotherapy Physicist, Barts Health NHS Trust
  • Investigating the optimal prescription isodose for linac-based SRS
    Dan Welsh, Higher Principal Clinical Scientist, The Christie NHS Foundation Trust
  • One isocenter to treat them all: a 10 year retrospective study of SRS for Multiple Brain Metastases
    Dr Paola Zuccoli, Radiation Oncologist, Ecomedica-Ergéa Group
  • CyberKnife Stereotactic Radiosurgery for Brainstem Metastases
    Mitchell Hickman, Consultant Radiographer – SRS, Queen Elizabeth Hospital Birmingham
4.55pmSession 6: AVMs

  • Stereotactic Radiosurgery for Persistent Paediatric AVMs: The Relevance of Previous Treatment Response on the Decision for Further Treatment, National Centre for Stereotactic Radiosurgery in Sheffield, UK
    David Eagle, Post-CCT Fellow in Neurosurgery, Sheffield Teaching Hospitals NHS Foundation Trust
  • Commissioning of an Arteriovenous Malformation (AVM) Service at the Bristol GammaKnife Centre
    Lucy Winch, Principal Clinical Scientist, Head of Dosimetry Development, Bristol Haematology and Oncology Centre
5.15pmHow we would treat: Discussion on the treatment of interesting clinical cases - benign
Chair: Dr Rovel Colaco, Consultant Clinical Oncologist, The Christie NHS Foundation Trust
Panel: Julian Cahill, Consultant, The National Centre for Stereotactic Radiosurgery, Ian Paddick, Consultant Physicist, Medical Physics Limited, Dr Sara Meade, Consultant Neuro-Oncologist, University Hospitals Birmingham, and Dr Matthew Williams, Consultant Clinical Oncologist, Imperial College Healthcare NHS Trust
6.00pmBusiness meeting
6.30pmClose
7.30pmMeeting Dinner
Victoria and Albert Hotel

Friday 30 January - Day two
8.30am
Registration, refreshments, exhibition and poster viewing
8.55amWelcome and introduction
Dr Matthew Williams, Consultant Clinical Oncologist, Imperial College Healthcare NHS Trust, and Julian Cahill, Consultant, The National Centre for Stereotactic Radiosurgery
9.00am 		Session 7: Systemic therapies and patterns of care

  • Sequencing radiosurgery with systemic therapy in melanoma brain metastases
    Professor Mark Pinkham, Radiation Oncologist, Princess Alexandra Hospital and Icon Cancer Centre, Australia
  • Access to stereotactic radiosurgery centres across the United Kingdom – an investigation of travel time
    Dr Stephen Robinson, Senior Clinical Oncology Registrar and Medical Doctoral Fellow, Sussex Cancer Centre, University Hospitals Sussex NHS Foundation Trust and University of Sussex
  • Radionecrosis in brain tumours: National insights on care provision and access to bevacizumab in the United Kingdom
    Dr Sarah Kingdon, Clinical Fellow, Tessa Jowell Brain Cancer Mission
  • Radiosurgery for Brain Metastases: From Few to Many — The New Normal?
    Ana Luis, Physicist, Medical Physics Limited
9.55am
Session 8: Pituitary Adenomas

  • Keynote: Endocrine outcomes after surgery – awaiting title
    Professor Karim Meeran, Professor of Endocrinology, Imperial College Healthcare NHS Trust
  • Keynote: Endocrine outcomes after SRS
    Professor Jean Régis, Professor of Neurosurgery, Aix Marseille University, France
  • Discussion

10.45amRefreshments, exhibition and poster viewing
11.15am
Session 9: Sponsored Presentations (II)

  • Technologies that positively impact clinical outcomes
    Gerrit Hombrink, Senior Product Manager RT Planning Solutions, Brainlab
  • Sponsored session – Accuray
  • Zap- X Gyroscopic Radiosurgery- No Compromise!
    David Miles, Director, Europe, ZAP Surgical
11.50amSession 10: Vestibular Schwannoma

  • Keynote: SRS for vestibular schwannoma: Large tumours, retreatment with SRS, what are our organs at risk?
    Professor Jean Régis, Professor of Neurosurgery, Aix Marseille University, France
  • Delivering Quality Assurance for the NHS England SRS Commissioning Programme: Outcomes and Lessons
    Luke Gilling, Medical Physicist, RTTQA
12.30pmLunch, exhibition and poster viewing
1.15pmSession 11: SRS for Functional Disorders

  • Keynote: SRS for movement disorders
    Professor Jean Régis, Professor of Neurosurgery, Aix Marseille University, France
  • Evaluation of Elements’ MRI distortion correction in radiosurgery planning
    Dr Abdul Hussein Mroué, Lead SRS Physicist, GenesisCare
  • Initial experience of using Cyberknife to deliver prolonged fractionation
    Mitchell Hickman, Consultant Radiographer – SRS, Queen Elizabeth Hospital Birmingham
2.00pmSession 12: Treatment planning and other topics

  • Planning a vestibular schwannoma with Gamma Knife – live demonstration
    Ian Paddick, Consultant Physicist, Medical Physics Limited
  • How we do it: Planning a vestibular schwannoma with the Cyberknife
    Dr Paul Sanghera, Consultant Clinical Oncologist, University Hospitals Birmingham, and Timothy Jackson, Principal Clinical Scientist for Cyberknife, University Hospitals Birmingham
  • How we do it: Planning a vestibular schwannoma with a linac
    Dr Abdul Hussein Mroué, Lead SRS Physicist, GenesisCare
  • Discussion
2.50pmSession 13: Quality of life and Patient-Reported Outcome Measures in SRS

  • Capturing quality-of-life and experience pre-SRS in patients diagnosed with brain metastases
    Kerlann Le Calvez, Research Associate, Imperial College Healthcare NHS Trust
  • Outcomes for Patients with Frailty Receiving SRS for Brain Metastases
    Catherine Fell, The Christie NHS Foundation Trust
  • Cognitive Decline after Brain Radiosurgery (CoDeB-Rad) at 3 months: Cognitive and Quality of Life (QoL) data
    Anna Bangiri, Principal SRS Radiotherapy Physicist, PhD Fellow, University of Nottingham, Nottingham University Hospitals NHS Trust 
  • Hippocampal Dosimetry and Neurocognitive Function in Patients undergoing Stereotactic Radiosurgery
    Dr Najmus Sahar Iqbal, Consultant Clinical Oncologist, Velindre University NHS Trust
3.30pmRefreshments, exhibition and poster viewing
3.50pmWhat are the challenges and opportunities for equitable SRS access? Insights from the Tessa Jowell Brain Cancer Mission
Dr Nicky Huskens, CEO, Tessa Jowell Brain Cancer Mission
4.10pmUpdate on DVLA driving restrictions post SRS 
Julian Cahill, Consultant, The National Centre for Stereotactic Radiosurgery
4.30pmClosing remarks
Dr Matthew Williams, Consultant Clinical Oncologist, Imperial College Healthcare NHS Trust, and Julian Cahill, Consultant, The National Centre for Stereotactic Radiosurgery